Patents by Inventor Brian A. McKittrick

Brian A. McKittrick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080076750
    Abstract: The present invention relates to methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering a compound having the formula or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof, wherein: R1 and R2 are defined in Tables 1-6 herein, and R3 is -phenyl, -4-chlorophenyl, -2-pyridyl, or -3-pyridyl.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 27, 2008
    Inventors: Robert Aslanian, Tin-Yau Chan, Joel Harris, Brian McKittrick, Bernard Neustadt, Anandan Palani, Tony Priestley, Elizabeth Smith, Andrew Stamford, Henry Vaccaro, Dong Xiao
  • Publication number: 20080076751
    Abstract: The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 27, 2008
    Inventors: Robert Aslanian, Chad Bennett, Duane Burnett, Tin-Yau Chan, Eugenia Kiselgof, Chad Knutson, Joel Harris, Brian McKittrick, Anandan Palani, Elizabeth Smith, Henry Vaccaro, Dong Xiao, Hyunjin Kim
  • Publication number: 20080070888
    Abstract: Disclosed are compounds of the formula wherein Z1 is —CH2— or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein. Also disclosed are methods of treating pain using a compound of formula I.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 20, 2008
    Inventors: Brian McKittrick, Elizabeth Smith, Chad Bennett, Duane Burnett, Chad Knutson
  • Publication number: 20080070892
    Abstract: Disclosed is a method of treating a disease or condition (e.g., pain, diabetes or disorders of lipid metabolism) comprising administering an azetidine derivative of the formula I selected from the group consisting of the compounds defined by Tables 1, 2, 3a, 3b, 3c, 3d and 4a.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 20, 2008
    Inventors: Joel Harris, Bernard Neustadt, Stephen Sorota, Andrew Stamford, Deen Tulshian, Brian McKittrick
  • Publication number: 20080070889
    Abstract: Disclosed are compounds of the formula wherein Z1 is —CH2— or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein. Also disclosed are methods of treating pain, and methods of inhibiting the absorption of cholesterol using a compound of formula I.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 20, 2008
    Inventors: DUANE BURNETT, Brian McKittrick
  • Publication number: 20080070890
    Abstract: The present invention relates to Spirocyclic Azetidinone Compounds, compositions comprising a Spirocyclic Azetidinone Compound and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of a Spirocyclic Azetidinone Compound.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 20, 2008
    Inventors: Duane A. Burnett, Brian A. McKittrick
  • Publication number: 20080019978
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
    Type: Application
    Filed: June 29, 2007
    Publication date: January 24, 2008
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying Huang, Robert Aslanian, Brian McKittrick, Sylvia Degrado
  • Publication number: 20080021019
    Abstract: Disclosed is a compound of the formula: and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered in combination with at least one addition pharmaceutically active ingredient.
    Type: Application
    Filed: March 28, 2007
    Publication date: January 24, 2008
    Inventors: Tin-Yau Chan, Brian McKittrick, Haiyan Pu, Liwu Hong, Andrew Prongay, Li Xiao, Mark McCoy
  • Publication number: 20080004257
    Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.
    Type: Application
    Filed: January 24, 2006
    Publication date: January 3, 2008
    Inventors: Tin-Yau Chan, Thierry Fischmann, Mark McCoy, Brian McKittrick, Andrew Prongay, Haiyan Pu, Li Wang, Li Xiao
  • Publication number: 20070287692
    Abstract: Disclosed are compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R1, R2, R6, R7, R30 and R31 are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
    Type: Application
    Filed: June 7, 2007
    Publication date: December 13, 2007
    Inventors: Yusheng Wu, Ulrich Iserloh, Jared Cumming, Xiaoxiang Liu, Robert Mazzola, Zhong-Yue Sun, Ying Huang, Andrew Stamford, Brian McKittrick, Zhaoning Zhu
  • Publication number: 20070099875
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W, R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
    Type: Application
    Filed: October 30, 2006
    Publication date: May 3, 2007
    Inventors: Zhaoning Zhu, Andrew Stamford, Brian McKittrick
  • Publication number: 20070099898
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Ar, R1, R2, R3, R4 and R5 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
    Type: Application
    Filed: October 25, 2006
    Publication date: May 3, 2007
    Inventors: Zhaoning Zhu, Andrew Stamford, Brian McKittrick
  • Publication number: 20070072852
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.
    Type: Application
    Filed: December 13, 2004
    Publication date: March 29, 2007
    Inventors: Zhaoning Zhu, Brian McKittrick, Zhong-Yue Sun, Yuanzan Ye, Johannes Voigt, Corey Strickland, Elizabeth Smith, Andrew Stamford, William Greenlee, Robert Mazzola, John Caldwell, Jared Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Tao Guo, Thuy Le, Kurt Saionz, Suresh Babu, Rachael Hunter
  • Publication number: 20070066630
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: ?pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
    Type: Application
    Filed: November 15, 2006
    Publication date: March 22, 2007
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying Huang, Robert Aslanian, Brian McKittrick, Sylvia Degrado
  • Publication number: 20070060575
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R1, R2, R3, R4, R6, R7 and R7a are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
    Type: Application
    Filed: June 12, 2006
    Publication date: March 15, 2007
    Inventors: Zhaoning Zhu, Brian McKittrick, Andrew Stamford, William Greenlee, Xiaoxiang Liu, Mihirbaran Mandal, Johannes Voigt, Corey Strickland
  • Publication number: 20070010667
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein A is a bond, —C(O)—, or —C(R3?)(R4?)—; X is —N(R1)— or —C(R6)(R7)—; Y is —S(O)2—, —C(?O)—, —PO(OR9) or —C(R6?R7?)—; is a single or double bond and R, R1, R2, R3, R4, R3?, R4?, R5, R6, R6?, R7 and R7? are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.
    Type: Application
    Filed: June 12, 2006
    Publication date: January 11, 2007
    Inventors: Brian McKittrick, Zhaoning Zhu, Andrew Stamford, Elizabeth Smith
  • Publication number: 20060287294
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, A, R, R1, R2, R6a and R7, are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
    Type: Application
    Filed: June 12, 2006
    Publication date: December 21, 2006
    Inventors: Zhaoning Zhu, Brian McKittrick, Andrew Stamford, Tao Guo, Thuy Le
  • Publication number: 20060281730
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, R, R1, R2, R3 and R4 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
    Type: Application
    Filed: June 12, 2006
    Publication date: December 14, 2006
    Inventors: Zhaoning Zhu, Brian McKittrick, Andrew Stamford, Ying Huang, Elizabeth Smith
  • Publication number: 20060264489
    Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
    Type: Application
    Filed: May 11, 2006
    Publication date: November 23, 2006
    Inventors: Anandan Palani, Jing Su, Dong Xiao, Xianhai Huang, Ashwin Rao, Xiao Chen, Haiqun Tang, Jun Qin, Ying Huang, Robert Aslanian, Brian McKittrick
  • Publication number: 20060252778
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Application
    Filed: June 1, 2005
    Publication date: November 9, 2006
    Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert Mazzola, Tin-Yau Chan, Henry Vaccaro, Brian McKittrick, Joseph Kozlowski, Brian Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline Ting, Kristin Rosner, Gerald Shipps, M. Siddiqui, David Belanger, Chaoyang Dai, Dansu Li, Vinay Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao